Federico Volpi, Juan Alcalde, Javier Larrache, Estíbaliz Alegre, Allan Argueta, María D. Lozano, Carla Colombo, Juan C. Galofré
{"title":"跟踪低危和中危分化型甲状腺癌的动态演变：识别有复发风险的个体","authors":"Federico Volpi, Juan Alcalde, Javier Larrache, Estíbaliz Alegre, Allan Argueta, María D. Lozano, Carla Colombo, Juan C. Galofré","doi":"10.1111/cen.15111","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The generally good prognosis of low- and intermediate-risk differentiated thyroid cancer (DTC) underscored the need to identify those few patients who relapse.</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>Records of 299 low- or intermediate-risk DTC patients (mean follow-up 8.2 ± 6.2 years) were retrospectively reviewed. The sample was classified following the American Thyroid Association (ATA) dynamic risk stratification (DRS) system.</p>\n </section>\n \n <section>\n \n <h3> Patients and Measurement</h3>\n \n <p>After classifying patients according to DRS at the first visit following initial therapy (FU1), structural recurrence occurred in 2/181 (1.1%), 5/81 (6.2%) and 13/26 (50.0%) with excellent, indeterminate and biochemical incomplete response to treatment, respectively. All relapses but one happened within 5 years from FU1. Univariate analysis comparing excellent, indeterminate and biochemical incomplete with structural incomplete responses at the end of the follow-up, identified tumour size (<i>p</i> < .001), <i>T</i> status (<0.001), positive lymph nodes (<i>N</i>) (<i>p</i> < .01), multifocality (<i>p</i> < .004), need of additional radioactive iodine (RAI) (<i>p</i> < .0001) and first DRS status (<i>p</i> < .0003) as risk factors of recurrence. In the multivariate analysis, only RAI remained statistically significant (<i>p</i> < .02). Comparison between excellent and indeterminate with biochemical and structural incomplete responses, identified tumour size (<i>p</i> < .0004), <i>T</i> (<i>p</i> < .01), <i>N</i> (<i>p</i> < .0001), bilaterality (<i>p</i> < .03), first DRS status (<i>p</i> < .0001) and RAI (<i>p</i> < .001) as recurrence risk factors. <i>T</i> (<i>p</i> < .01) and first DRS (<i>p</i> < .0006) were confirmed in the multivariate analysis.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Patients with DTC classified as low- or intermediate-risk of recurrence with excellent response to treatment at FU1 rarely develop structural disease and this occurs almost exclusively in the first 5 years. Initial DRS status is an accurate tool for determining the risk of recurrence.</p>\n </section>\n </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cen.15111","citationCount":"0","resultStr":"{\"title\":\"Tracking dynamic evolution of low- and intermediate-risk differentiated thyroid cancer: Identification of individuals at risk of recurrence\",\"authors\":\"Federico Volpi, Juan Alcalde, Javier Larrache, Estíbaliz Alegre, Allan Argueta, María D. Lozano, Carla Colombo, Juan C. Galofré\",\"doi\":\"10.1111/cen.15111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>The generally good prognosis of low- and intermediate-risk differentiated thyroid cancer (DTC) underscored the need to identify those few patients who relapse.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Design</h3>\\n \\n <p>Records of 299 low- or intermediate-risk DTC patients (mean follow-up 8.2 ± 6.2 years) were retrospectively reviewed. The sample was classified following the American Thyroid Association (ATA) dynamic risk stratification (DRS) system.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Patients and Measurement</h3>\\n \\n <p>After classifying patients according to DRS at the first visit following initial therapy (FU1), structural recurrence occurred in 2/181 (1.1%), 5/81 (6.2%) and 13/26 (50.0%) with excellent, indeterminate and biochemical incomplete response to treatment, respectively. All relapses but one happened within 5 years from FU1. Univariate analysis comparing excellent, indeterminate and biochemical incomplete with structural incomplete responses at the end of the follow-up, identified tumour size (<i>p</i> < .001), <i>T</i> status (<0.001), positive lymph nodes (<i>N</i>) (<i>p</i> < .01), multifocality (<i>p</i> < .004), need of additional radioactive iodine (RAI) (<i>p</i> < .0001) and first DRS status (<i>p</i> < .0003) as risk factors of recurrence. In the multivariate analysis, only RAI remained statistically significant (<i>p</i> < .02). Comparison between excellent and indeterminate with biochemical and structural incomplete responses, identified tumour size (<i>p</i> < .0004), <i>T</i> (<i>p</i> < .01), <i>N</i> (<i>p</i> < .0001), bilaterality (<i>p</i> < .03), first DRS status (<i>p</i> < .0001) and RAI (<i>p</i> < .001) as recurrence risk factors. <i>T</i> (<i>p</i> < .01) and first DRS (<i>p</i> < .0006) were confirmed in the multivariate analysis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Patients with DTC classified as low- or intermediate-risk of recurrence with excellent response to treatment at FU1 rarely develop structural disease and this occurs almost exclusively in the first 5 years. Initial DRS status is an accurate tool for determining the risk of recurrence.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10346,\"journal\":{\"name\":\"Clinical Endocrinology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cen.15111\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Endocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cen.15111\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen.15111","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Tracking dynamic evolution of low- and intermediate-risk differentiated thyroid cancer: Identification of individuals at risk of recurrence
Objective
The generally good prognosis of low- and intermediate-risk differentiated thyroid cancer (DTC) underscored the need to identify those few patients who relapse.
Design
Records of 299 low- or intermediate-risk DTC patients (mean follow-up 8.2 ± 6.2 years) were retrospectively reviewed. The sample was classified following the American Thyroid Association (ATA) dynamic risk stratification (DRS) system.
Patients and Measurement
After classifying patients according to DRS at the first visit following initial therapy (FU1), structural recurrence occurred in 2/181 (1.1%), 5/81 (6.2%) and 13/26 (50.0%) with excellent, indeterminate and biochemical incomplete response to treatment, respectively. All relapses but one happened within 5 years from FU1. Univariate analysis comparing excellent, indeterminate and biochemical incomplete with structural incomplete responses at the end of the follow-up, identified tumour size (p < .001), T status (<0.001), positive lymph nodes (N) (p < .01), multifocality (p < .004), need of additional radioactive iodine (RAI) (p < .0001) and first DRS status (p < .0003) as risk factors of recurrence. In the multivariate analysis, only RAI remained statistically significant (p < .02). Comparison between excellent and indeterminate with biochemical and structural incomplete responses, identified tumour size (p < .0004), T (p < .01), N (p < .0001), bilaterality (p < .03), first DRS status (p < .0001) and RAI (p < .001) as recurrence risk factors. T (p < .01) and first DRS (p < .0006) were confirmed in the multivariate analysis.
Conclusions
Patients with DTC classified as low- or intermediate-risk of recurrence with excellent response to treatment at FU1 rarely develop structural disease and this occurs almost exclusively in the first 5 years. Initial DRS status is an accurate tool for determining the risk of recurrence.
期刊介绍：
Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
